Increased participation by retail is a positive development. Let's not regulate or legislate that progress away.

I see increased participation in our capital markets as a positive development for wealth creation.

Government can and must provide opportunity, not smother it; foster productivity, not stifle it.

I have real concerns that the CLEAN Future Act puts the cart before the horse by mandating electric vehicles.

The last thing we want to do is take away people's mobility and livelihoods by limiting options of affordable and reliable vehicles.

Thank you. And I just want to reinforce for everyone, you ought to read this United Nations report, because it really does document very clearly some of the problems that we are foisting on other nations, instead of doing it ourselves.

The big question is how are we supposed to build these electric vehicles here at home?

We need regulatory reform to mine and process critical minerals at home.

But I could tell you, Mr. Chairman, maybe it is time they look in the mirror and ask themselves why are they denying these devastating environmental and human right abuses in order to obtain the critical minerals needed for batteries?

Look, this road to get 100 percent EVs and renewables is littered with environmental damage and human rights abuses.

We should let the market and consumer choice drive the adoption of EVs.

Isn't it time to be honest with the American people about the raw materials needed to make these batteries, where they come from, and the consequences of extracting these raw materials?

So we know the loser here is going to be the American public if we don't get a bill to the President's desk for signature.

Policies like referencing pricing and government price-settings will effectively turn our biopharma industry to a risk-averse, think-inside-the-box-rather-than-outside-the-box commodity industry.

H.R. 3, unfortunately, is an overreach, and unfortunately it gives me the impression, for those in the package, that Congress is seemingly willing to let American patients suffer.

Healthcare is a right for everyone, and access to prescription medication should not be reserved as a privilege only for the wealthy few.

We need a robust biopharma industry, and I think everyone agrees to that, investing in rare diseases.

The status quo is not acceptable. Congress must act to ensure that the American people have access to and can afford the treatments that they need.